KLISBio to share innovative tissue-engineered technology at BIO Partnering with JP Morgan

KLISBio will showcase its silk-based biomedical technology at JP Morgan's BIO Partnering conference, positioning itself among cutting-edge life sciences innovations being presented to investors and healthcare decision-makers.

The company is developing SILKBridge, described as a first-to-market, silk-based graft for peripheral nerve repair anticipated for clinical availability in 2023. This tissue-engineered product utilizes pure silk fibroin, combining traditional knowledge with contemporary biotechnology to create a highly purified biomedical material that avoids chemical cross-linking processes.

KLISBio operates a multidisciplinary silk-based platform addressing multiple clinical needs including peripheral nerve injuries, vascular diseases, bone defects, and tendon repairs requiring sustained drug delivery solutions.

CEO Gabriele Grecchi stated the company is significantly contributing to healthcare innovation, disrupting the restorative surgical market through its versatile biocompatible material and scientific rigor.

The organization is led by internationally recognized medtech experts including Grecchi as CEO, Antonio Alessandrino as CTO, Giuliano Freddi as CSO, and Jason Schense as CBO. Rodrigo Bianchi recently joined as Board Chairman, bringing over thirty years of global healthcare experience.